Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Revenue of $5.2 million- Gross margin of 33%- Adjusted EBITDA margin of 3%- Awarded three new projects HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Koil Energy...
-
HOUSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), announced today that it will file its Quarterly Report on Form 10-Q for the second quarter of 2025 on Thursday,...
-
HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its first...
-
HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, announced today that it will...
-
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Unisys Corporation (“Unisys” or the “Company”) (NYSE:...
-
NEW YORK, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Provident Bancorp, Inc. (“Provident” or “Company”)...
-
CHICAGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ:IPDN), (“IPDN” or the “Company”), a global developer and operator of online and in-person networks that...
-
LAS VEGAS, NV, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (OTC: MSSV), a technology and numismatic company specializing in the...
-
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...
-
-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of...